Therefore, in breast cancers it is strongly recommended that IHC +2 cases are confirmed by FISH for a more appropriate selection of candidate patients for targeted therapy, for instance with the anti Her-2 monoclonal antibody Trastuzumab [36]. Here, ERBB2 is linked to breast cancer.